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Enhanced External
Counterpulsation and Future Directions
Step Beyond Medical Management
for Patients With Angina and Heart Failure
Aarush Manchanda, MD,* Ozlem Soran, MD, MPH, FACC, FESC†
Washington, DC; and Pittsburgh, Pennsylvania
Between 25,000 and 75,000 new cases of angina refractory to maximal medical therapy and standard coronary
revascularization procedures are diagnosed each year. In addition, heart failure also places an enormous burden
on the U.S. health care system, with an estimated economic impact ranging from $20 billion to more than $50
billion per year. The technique of counterpulsation, studied for almost one-half century now, is considered a safe,
highly beneficial, low-cost, noninvasive treatment for these angina patients, and now for heart failure patients as
well. Recent evidence suggests that enhanced external counterpulsation (EECP) therapy may improve symptoms
and decrease long-term morbidity via more than 1 mechanism, including improvement in endothelial function,
promotion of collateralization, enhancement of ventricular function, improvement in oxygen consumption (VO2),
regression of atherosclerosis, and peripheral training effects similar to exercise. Numerous clinical trials in the
last 2 decades have shown EECP therapy to be safe and effective for patients with refractory angina with a clini-
cal response rate averaging 70% to 80%, which is sustained up to 5 years. It is not only safe in patients with
coexisting heart failure, but also is shown to improve quality of life and exercise capacity and to improve left ven-
tricular function long-term. Interestingly, EECP therapy has been studied for various potential uses other than heart
disease, such as restless leg syndrome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on. This
review summarizes the current evidence for its use in stable angina and heart failure and its future
directions. (J Am Coll Cardiol 2007;50:1523–31) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.024n
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mn estimated 6.4 million patients in the U.S. suffer from
ymptomatic coronary artery disease (CAD), and about
00,000 new cases develop each year (1). Despite optimal
edical therapy and invasive procedures, such as angioplasty
nd cardiac bypass surgery, there are an estimated 300,000
o 900,000 patients in the U.S. who have refractory angina
ectoris (RAP). About 25,000 to 75,000 new cases of RAP
re diagnosed each year (1).
Daily tasks such as climbing a flight of stairs, walking
dog, or mowing the lawn become impossible without
xperiencing chest pain for these difficult-to-treat pa-
ients. In addition, despite advances in medical therapy
or the treatment of heart failure (HF) over the past
ecade, substantial unmet needs remain, particularly in
atients with moderate to severe HF. Heart failure is the
umber 1 diagnosis in Medicare patients and approxi-
ately 5 million Americans experience HF, with 550,000
rom the *Department of Internal Medicine, The George Washington University,
ashington, DC; and the †Cardiovascular Institute, University of Pittsburgh
edical Center, Pittsburgh, Pennsylvania. Dr. Soran serves on the Speakers’ Bureau
f Vasomedical, Inc.d
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ccepted July 17, 2007.ew cases per year reported (1). It has been estimated that
n 2005, the total direct and indirect cost of HF in the
.S. will be equal to $27.9 billion, and approximately
2.9 billion annually is spent on drugs for the treatment
f HF (1). Only a few consensus therapies exist to treat
F beyond medical management, and many patients now
re left to suffer their symptoms and restrict their
ctivities chronically, and anticipate a reduced life
xpectancy.
Current nonpharmacological options available for
hese patients with RAP with or without underlying HF
nclude neurostimulation (transcutaneous electrical nerve
timulation and spinal cord stimulation), enhanced ex-
ernal counterpulsation (EECP) therapy, laser revascu-
arization techniques, gene therapy, and newer interven-
ional procedures such as percutaneous in situ coronary
enous arterialization or percutaneous in situ coronary
rtery bypass (2). Of these modalities, EECP therapy
epresents the only truly noninvasive technique for which
oth a reduction of angina symptoms, improvement in
bjective measures of myocardial ischemia, and improve-
ent in left ventricular function (both systolic andiastolic) have been shown (3–5). This review summa-
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EECP and Future Directions October 16, 2007:1523–31rizes the current evidence for
the use of EECP therapy in
stable angina and HF and its
future directions.
Historical Perspective
Almost one-half century ago, re-
searchers at Harvard University
conducted experiments with
counterpulsation showing that
this technique markedly reduces
the workload, and thus oxygen
consumption, of the left ventri-
cle. In 1953, Kantrowitz and
Kantrowitz (6) described dia-
stolic augmentation as a means
of improving coronary blood
ow. Birtwell et al. (7) did pioneering work toward the
evelopment of this technique and were first to apply this
oncept by developing the initial arterial counterpulsator in
he U.S. Zheng et al. (8) were the first to report the benefits
f external counterpulsation in the 1980s by using the first
neumatic counterpulsation device. Lawson et al. (9–13) at
he State University of New York, Stony Brook, undertook
number of open-label studies with the enhanced system,
ECP, between 1989 and 1998 using both objective and
ubjective end points. These studies, although open and
onrandomized, showed statistical improvement in exercise
olerance by patients as evidenced by thallium-stress testing
nd partial or complete resolution of coronary perfusion
efects as evidenced by radionuclide imaging studies. In
999, Arora et al. (14) reported results of the first double-
Abbreviations
and Acronyms
CAD  coronary artery
disease
cGMP  cyclic guanosine
monophosphate
EECP  enhanced external
counterpulsation
EF  ejection fraction
HF  heart failure
LVD  left ventricular
dysfunction
NYHA  New York Heart
Association
RAP  refractory angina
pectoris
Figure 1 Technique of EECP
Three pairs of pneumatic cuffs are applied to the calves, lower thighs, and upper
pression of the lower-extremity vascular bed increases diastolic pressure and flow
Inflation and deflation are timed according to the R-wave on the patient’s cardiac m
using the pressure waveforms and electrocardiogram on the enhanced external colind randomized placebo-controlled multicenter trial
MUST-EECP [Multicenter Study of Enhanced External
ounterpulsation]) (14). Since then, EECP therapy has
merged as an effective, noninvasive, and durable therapeutic
ption for patients not only with angina but also with HF.
echnique
he technique of EECP therapy consists of electro-
ardiogram-gated rapid, sequential compression of the lower
xtremities taking place during diastole, followed by simulta-
eous decompression during systole. These actions produce
emodynamic effects similar to those of an intraaortic balloon
ump, but unlike an intra-aortic balloon pump, EECP therapy
lso increases venous return (Fig. 1).
Cuffs resembling oversized blood pressure cuffs—on the
alves, the lower thighs, and the upper thighs, including the
uttocks, inflate rapidly and sequentially—via computer-
nterpreted electrocardiogram signals—starting from the
alves and proceeding upward to the buttocks (Fig. 1)
uring the resting phase of each heartbeat (diastole). This
as the effect of creating a strong retrograde counterpulse in
he arterial system, forcing freshly oxygenated blood toward
he heart and coronary arteries, while simultaneously in-
reasing the volume of venous blood return to the heart
nder increased pressure.
Just before the next heartbeat, before the systole, all 3
uffs simultaneously deflate, significantly reducing the
orkload of the heart. This is achieved because the vascular
eds in the lower extremities are relatively empty when the
uffs are deflated, significantly lowering the resistance to
lood ejected by the heart, reducing the amount of work the
eart must do to pump oxygenated blood to the rest of
The cuffs are inflated sequentially during diastole, distal to proximal. The com-
creases venous return. The pressure is then released at the onset of systole.
r. The pressures applied and the inflation–deflation timing can be altered by
ulsation (EECP) therapy monitor.thighs.
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October 16, 2007:1523–31 EECP and Future Directionshe body. The inflation-deflation activity is monitored with
he help of a finger plethysmogram and coordinated by a
icroprocessor that interprets electrocardiogram signals
rom the patient’s heart and actuates the inflation and
eflation cycles. The end result of this sequential squeezing
f the legs is to create a pressure wave that significantly
ncreases peak diastolic pressure, benefiting circulation to
he heart muscle and other organs, while also reducing
ystolic pressure and systemic vascular resistance to the
eneral benefit of the vascular system. A typical treatment
ourse consists of 35 outpatient treatments administered as
h per day over 7 weeks.
echanism of Action of EECP
ecent advances in the understanding of coronary arterial
hysiology and response to EECP therapy have provided
ome insight into possible modes of effect and an explana-
ion for the benefits seen with EECP therapy (Fig. 2.)
owever, most of the experience is from small animal or
uman uncontrolled studies, and the mechanism of the
ustained antianginal benefit with EECP remains unclear.
Development of new functional collateral vessels by
ncreasing nitric oxide and decreasing endothelin-1 levels to
he ischemic myocardium was postulated as the mechanism
f action for EECP therapy by many early studies con-
ucted. Masuda et al. (15) reported that the development of
unctional collateral vessels is one of the mechanisms of
ECP therapy using ammonia positron emission tomogra-
Figure 2 Possible Mechanisms Responsible for the
Clinical Benefit Associated With EECP Therapy
Acute afterload reduction decreases myocardial demand. By increasing coro-
nary blood flow, enhanced external counterpulsation (EECP) therapy is thought
to promote myocardial collateralization via opening of preformed collateral ves-
sels, arteriogenesis, and angiogenesis. Increased blood flow and shear stress
also may improve coronary endothelial function, favoring vasodilation and myo-
cardial perfusion. In addition, improvement in endothelial function may further
promote collateral formation by arteriogenesis and angiogenesis. In addition to
a peripheral training effect, a minor placebo effect is considered to contribute
to the symptomatic benefit of EECP therapy. ET  endothelin; NO  nitric
oxide.shy. Endothelial shear stress from increased diastolic aug-
entation after EECP therapy was shown to augment
ndothelium-derived relaxing factor/nitric oxide production
16) and to cause down-regulation of endothelin-1 levels,
hereby recruiting more collateral vessels (17). Akhtar et al.
18) recently showed that EECP therapy has a sustained,
ose-related effect in stimulating endothelial cell production
f the vasodilator nitric oxide and in decreasing production
f endothelin-1. However, an increase in myocardial perfu-
ion on nuclear stress tests was inconsistent with improve-
ent in symptoms (Table 1), making it unlikely as a sole
echanism of benefit.
In recent studies by Tao et al. (19,20), EECP therapy
emonstrated stabilization of coronary endothelium, an
ffect very similar to that of athletic training. These recent
tudies confirm the earlier results by Bonetti et al. (21); they
ad seen improvement in the peripheral endothelial func-
ion (RH-PAT) in their patients after 35 h of EECP
reatment. Zhang et al. (22) also showed retardation of the
therosclerosis process by the metabolic effects of external
ounterpulsation therapy on the NF-kappa signaling path-
ays. Recently Levenson et al. (23) postulated that an
ncrease in cyclic guanosine monophosphate (cGMP)
cutely after EECP therapy might in part be responsible for
he improved peripheral arterial function. Cyclic guanosine
onophosphate regulates vascular smooth muscle tone,
hich may improve arterial function. Fifty-five subjects
ere randomized into 2 groups to receive either sham
control) or active EECP therapy during 1 h. Plasma and
latelet cGMP were measured immediately before and after
ECP therapy by radioimmunoassay. One hour of EECP
herapy increased cGMP plasma concentration by 52% and
latelet content by 19%. This theory of endothelial stabili-
ation has attracted the most attention in the recent past as
ne of the primary mechanisms of action, with more clinical
rials needed to further understand it completely.
Arora et al. (24) showed a trend toward increased vascular
ndothelial growth factor levels after EECP therapy in human
ubjects, thereby confirming the findings of Chen et al. (25) in
he canine model. Vascular endothelial growth factor, along
ith other growth factors such as fibroblast growth factor, is
he most widely studied in gene therapy for RAP. It is
onsidered important in promoting angiogenesis or neorevas-
ularization of the ischemic myocardium. However, failure to
how consistent improvement in myocardial perfusion as dis-
ussed above makes neorevascularization unlikely, an argument
imilar to the one against collateralization.
Ochoa et al. (26) recently reported the acute effects of
ECP therapy on oxygen uptake: VO2 at rest in adults with
ymptomatic CAD compared with healthy volunteers using
ham control group. They measured VO2 continuously in 20
dults during a single treatment session of EECP therapy,
ncluding 10 subjects with previous coronary revasculariza-
ion who were referred for EECP therapy for refractory
ngina and 10 healthy, sedentary volunteers. Both groups
howed a small, sustained increase in VO2 during EECP
P*
c
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Table 1 Published Trials of EECP in Patients With Stable Angina
Study (Ref. #) Year N
Treatment
Duration
(h)
Angina
Relief
(% >1 CCS
Class1)
Nitroglycerine
Use Versus
Frequency
Exercise
Capacity
(%)
Time to
ST-Segment
Depression
on Stress
Test
Cardiac Perfusion
(% of Patients) Other Findings
Zheng et al. (8) 1983 200 12 2 (97%) NA NA NA NA —
Lawson et al.
(10)
1992 18 36 2(100%) 2 167 NA 1 (78%) —
Lawson et al.
(11,12)
1996 27 35 NA NA 181 NA 1 (78%) In addition, EECP
therapy seemed to
decrease PVR and HR
response to exercise,
the so-called training
effect
Lawson et al.
(13)
1998 60 35 2 NA 1 NA 1 (75%) Benefit sustained at 2-yr
follow-up
Arora et al.
(14)
1999 139 35 2 2 1 1 NA Only double-blind trial to
date using sham
controls
Lawson et al.
(27)
2000 33 35 2 (100%) 2 NA NA 1 (79%) Benefit sustained at 5-yr
follow-up
Lawson et al.
(28)
2000 2,289 35 2 (74%) NA NA NA NA EECP consortium.
Efficacy was
independent of
provider setting or
experience
Masuda et al.
(29)
2001 11 35 NA NA 1 1 1 Coronary perfusion
increased both at
baseline and during
dipyridamole
provocation
Stys et al. (30) 2001 395 35 2 (88%) NA NA NA NA EECP was equally
effective in men and
women and young
and elderly (65 yrs)
Barsness et al.
(31)
2001 978 35 2 (81%) 2 NA NA NA EECP therapy can be
used for those who
prefer noninvasive
treatment to avoid
revascularization
Stys et al. (32) 2002 175 35 2 (85%) NA 1 NA 1 (83%) —
Fitzgerald et al.
(33)
2003 4,454 35 2* 2* NA NA 1 *Comparable benefit
seen for both
previously
revascularized and
PUMPERS
Tartaglia et al.
(34)
2003 25 35 2 (93%) NA 1 1 (80%) NA —
Lawson et al.
(35)
2006 363 35 2 (72%)* 2 52* NA NA NA *Benefit sustained at
2 yrs
Lawson et al.
(36)
2005 746 32 2 (72%) 2 NA NA NA Equal benefit in both
systolic and diastolic
heart failure
Novo et al. (37) 2006 25 35 2 (84%) NA NA NA 1 (36%) dobutamine
stress if possible
echocardiography
Maximal benefit seen in
patients with worst
systolic failure
Lawson et al.
(38)
2006 1,458 35 2 2 1 NA NA EECP therapy was found
to be equally
beneficial in mild vs.
severe anginal
symptoms
Loh et al. (39) 2006 58 35 2 (86%)* 2 1 NA NA *Sustained
improvement in 78%
at 1-yr follow-up
Comment related to the particular variable in the referenced study.
CCS  Canadian Cardiovascular Society; EECP  enhanced external counterpulsation; HR  heart rate; NA  not applicable; PUMPERS  candidates for percutaneous coronary intervention and/or
oronary artery bypass graft and chose enhanced external counterpulsation therapy as their initial revascularization treatment; PVR  peripheral vascular resistance.
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October 16, 2007:1523–31 EECP and Future Directionsreatment. Because VO2 is an independent predictor of
ncreased exercise capacity, it led them to conclude that
ncrease in VO2 may also in part be one of the mechanisms
y which EECP therapy increases exercise tolerance in
table angina patients (26).
In summary, further studies are needed to elucidate both
he mechanism of action and the overall effects of EECP
herapy, or a combination of the above mechanisms may
xplain the sustained benefit from EECP therapy in the
linical trials (27).
ECP and Angina
everal nonrandomized and randomized trials have shown a
onsistently positive clinical response among patients of
AP treated with EECP therapy (Table 1) (8–14,28–39).
enefits associated with EECP therapy include reduction of
ngina and nitrate use, increased exercise tolerance, favor-
ble psychosocial effects and enhanced quality of life, as well
s prolongation of the time to exercise-induced ST-segment
epression and an accompanying resolution of myocardial
erfusion defects (Table 1). Patients with severely disabling
ngina at baseline and those without a history of smoking
re more likely to improve their angina class after EECP
herapy (40).
Most of the studies on EECP therapy cannot be double-
lind and lack good control groups because of technical
imitations, which have frequently raised questions of oper-
tor bias in the past. But the MUST-EECP study, a
andomized, double-blind, sham-controlled trial, also
howed the clinical benefit of EECP therapy in patients
ith chronic stable angina and positive exercise stress tests
14). In this study, 139 patients (mean age 63 years, range
5 years to 81 years) with angina pectoris (typical Canadian
ardiovascular Society classes I, II, and III angina) and
ocumented coronary ischemia were equally randomized to
emodynamically inactive counterpulsation with EECP
ersus active counterpulsation. Patients in the active EECP
herapy group showed a statistically significant increase in
ime to exercise-induced ST-segment depression when
ompared with sham and baseline, and reported a statisti-
ally significant decrease in the frequency of angina episodes
hen compared with sham and baseline. Exercise duration
ncreased significantly in both groups; however, the increase
as greater in the active EECP group. Moreover, a MUST-
ECP substudy showed a significant improvement in
uality-of-life parameters in patients assigned to active
reatment, which was sustained during a 12-month
ollow-up period (41).
Results from the International EECP Patient Registry
31,33,35) and the EECP Clinical Consortium (28) have
hown that the symptomatic benefit observed in controlled
tudies also translates to the heterogeneous patient popula-
ion seen in clinical practice. Moreover, follow-up data
ndicate that the clinical benefit may be maintained for up toyears in patients with a favorable initial clinical response m27,35). One of the ongoing debates with most of the
ublished trials discussed earlier (Table 1) is that the
ncreased exercise tolerance reported after EECP therapy
ay, at least in part, be attributed to a training effect.
ECP in Angina With Left Ventricular Dysfunction
hen providing EECP therapy to the HF population, the
rimary concern of the initial researchers was that the
ncreased venous return resulting from EECP therapy could
recipitate pulmonary edema in angina patients with severe
eft ventricular dysfunction (LVD). Soran et al. (42,43)
valuated the safety and efficacy of EECP therapy in
atients with angina and severe LVD (ejection fraction
EF] 35%). The outcomes of EECP treatment were
ollowed up in 363 patients enrolled in the International
ECP Patient Registry, an international multicenter study
f EECP therapy for the treatment of patients with chronic
ngina. The EECP therapy was observed to be a safe and
ffective treatment of angina in patients with severe LVD
ho were not considered good candidates for revasculariza-
ion by coronary artery bypass graft or percutaneous coro-
ary intervention (43). After completion of treatment, there
as a significant reduction in severity of angina: 72%
mproved from severe angina to no angina or mild angina.
ifty-two percent of patients discontinued nitroglycerin use.
uality of life showed a significant increase. At 2-year
ollow-up, this angina reduction was maintained in 55%,
3% survived, and event-free (death/myocardial infarction/
ercutaneous coronary intervention/coronary artery bypass
raft) survival rate was 70%. Forty-three percent had no
ardiac hospitalization; 81% had no congestive HF event
43).
Lawson et al. (44) also evaluated RAP patients with
reserved left ventricular function (EF 35%) and with
evere left ventricular dysfunction (EF 35%) who were
reated with a 35-h course of EECP therapy. Bioimpedance
easurements of cardiovascular function were obtained
efore the first and again after the 35th hour of EECP
herapy. Twenty-five patients were enrolled, 20 with pre-
erved left ventricular function and 5 with severe left
entricular dysfunction. Angina class improved similarly in
oth groups. The severe left ventricular dysfunction group,
n contrast to the preserved left ventricular function group,
ncreased cardiac power, stroke volume, and cardiac index
nd decreased systemic vascular resistance with treatment.
his study suggests that EECP could benefit patients
xperiencing CAD with severe left ventricular dysfunction
irectly by improving cardiac power and indirectly by
ecreasing systemic vascular resistance (44).
ECP Therapy in HF
ost of the data to date on the efficacy and safety of EECP
herapy in HF are from small studies (45,46). In a pilot
tudy of clinically stable patients diagnosed with mild to
oderate HF (New York Heart Association [NYHA]
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EECP and Future Directions October 16, 2007:1523–31unctional class II or III) and a left ventricular EF 35%,
oran et al. (45) found EECP treatment to be safe with no
nexpected adverse events during the application of EECP
reatment. Soran et al. (45) also conducted a multicenter
easibility study in which stable HF (New York Heart
ssociation functional class II to III, ischemic and nonisch-
mic etiology) patients with left ventricular EF 35% were
reated with 35 1-h sessions of EECP therapy over a 7-week
eriod and followed up over a 6-month period. The mean
F for the ischemic and nonischemic groups was 25.6 
.1% and 18.7  7.4%, respectively. Mild to moderate
alvular heart disease was the most common etiology for the
roup with nonischemic etiology. Study results showed that
ECP therapy was safe and well-tolerated in this group of
atients (46). In addition, EECP therapy was associated
ith significant improvements in exercise capacity as mea-
ured by peak oxygen uptake and exercise duration and in
uality of life at 1 week and 6 months after EECP
reatment. Although safety was the primary end point of
his feasibility study, the efficacy results suggest that EECP
herapy can increase peak oxygen uptake, improve exercise
apacity and functional status, as well as improve the
atient’s quality of life, for both the short term and long
erm (6 months) after the completion of EECP therapy.
lthough study subjects benefited from EECP therapy to a
imilar degree regardless of ischemic or nonischemic etiol-
gy of their HF, because of a small number of patients in
he nonischemic group, further studies need to be con-
ucted to evaluate the effectiveness of EECP in patients
ith a nonischemic etiology (46).
Based on these results, a larger, controlled study of
ECP therapy in patients with stable HF (NYHA
unctional classes II and III) and LVD was undertaken
alled the PEECH (Prospective Evaluation of EECP in
eart Failure) trial (47), results of which were recently
ide Effects and Contraindications of Enhanced External Counterpu
Table 2 Side Effects and Contraindications of Enhanced Extern
Side effects
Leg or waist pain
Skin abrasion or ecchymoses
Bruises in patients using Coumadin when INR dosage is not adjusted
Paresthesias
Worsening of heart failure in patients with severe arrhythmias
Contraindications
Coagulopathy with an INR of prothrombin time 2.5
Arrhythmias that may interfere with triggering of EECP system (uncontrolled atrial
Within 2 weeks after cardiac catheterization or arterial puncture (risk of bleeding
Decompensated heart failure
Moderate to severe aortic insufficiency (regurgitation would prevent diastolic augm
Severe peripheral arterial disease (reduced vascular volume and muscle mass ma
Severe hypertension 180/110 mm Hg (the augmented diastolic pressure may e
Aortic aneurysm (5 mm) or dissection (diastolic pressure augmentation may be
Pregnancy or women of childbearing age (effects of EECP therapy on fetus have n
Venous disease (phlebitis, varicose veins, stasis ulcers, prior or current deep vein
Severe chronic obstructive pulmonary disease (no safety data in pulmonary hyperECP  enhanced external counterpulsation; INR  international normalized ratio.ublished. It was a controlled, randomized, single-blind,
arallel-group, multicenter study of 187 patients with
ymptomatic but stable HF (NYHA functional classes II
nd III, ischemic and nonischemic etiology) and a left
entricular EF 35% was designed to assess the efficacy
f EECP therapy in patients with stable HF. Medical
herapy is optimized in all patients based on the recom-
endations of the Heart Failure Society of America
usual care), and then randomized between 2 treatment
roups, usual care or EECP therapy (35 h over 7 weeks).
he EECP therapy improved exercise tolerance, quality
f life, and NYHA functional class without an accompa-
ying increase in peak VO2. Investigators also assessed
hether differences existed in response to EECP therapy
n patients with HF secondary to either ischemic or
onischemic dilated cardiomyopathy. Albeit in a rela-
ively small sample size, subgroup analysis based on
tiology of disease showed benefit in patients with
schemic cardiomyopathy, whereas this difference was not
een in the small number of patients with nonischemic
isease. Because patients were not blinded to therapy,
hese benefits of EECP therapy may be attributable to a
lacebo effect. However, the usefulness of EECP therapy
y physicians must be individualized based on their
ssessment of the totality of EECP therapy data. Further
tudies may help elucidate both the mechanism of action
nd the overall effects of EECP therapy.
imitations of the Technique
t is important to point out that EECP therapy is not for
veryone. This noninvasive outpatient procedure can be
omewhat uncomfortable for patients because of the high-
ressure sequential compression of the cuffs. It is not
ecommended for certain types of valvular heart disease
on
unterpulsation
tion, flutter, and very frequent premature ventricular contractions)
oral puncture site)
ion)
ent effective counterpulsation, increased risk of thromboembolism)
safe limits)
rious)
n studied)
osis or pulmonary embolism)
)lsati
al Co
fibrilla
at fem
entat
y prev
xceed
delete
ot bee
thromb
tension
Future Directions and Potential Uses of EECP
Table 3 Future Directions and Potential Uses of EECP
Study (Ref. #) Year/Country Number of Patients
Treatment
Duration (h)
Potential Uses of EECP Therapy in Conditions
Other Than RAP and HF Remarks
Werner et al. (48) 2005/Germany 19 2 Hepatorenal syndrome
Safety: EECP therapy was tolerated by healthy and
cirrhotic patients alike
Efficacy: EECP therapy increased MAP and increased
urinary production (urinary flow rate) in patients
with end-stage cirrhosis and hepatorenal
syndrome
Potential role of EECP therapy in diuresis and increased
urinary flow in patients with end-stage liver disease who
are awaiting transplant
Rajaram et al. (49) 2005/U.S. 6 35 Restless leg syndrome
Relief of symptoms and change in the IRLS score
from 28.8 to 6.0 after EECP therapy
Benefit sustained for 6 months; IRLS score was 3.3
at the end of 6 months
It was a small, uncontrolled case series
Hilz et al. (50) 2004/Germany 38 1 Peripheral vasodilatation and skin effects similar to
those during exercise
Potential role of EECP therapy in improving vascular flow
in mild nonulcerative peripheral vascular disease
Nike Sports Research Lab (51) 2004/U.S. 19 vigorously active
men in training
35 Improvement in postural instability and ataxia in
EECP treatment group as compared with control
EECP therapy had no significant effect on the physiological
parameters considered to be the best for predicting
performance in endurance-type sportsmen: VO2, lactate
levels, work tolerance time
Froschermaier et al. (52) 1998/Germany 13 35 Increase in the penile artery flow by 200%, and
11 of 13 reported improved erectile function
Case series looking at EECP therapy and erectile
dysfunction
Offergeld et al. (53) 1998/Germany 30 5–10 Treatment of sudden deafness and tinnitus (vascular
in origin)
Hearing threshold increased in 28%, on average by 19 dB
Tinnitus decreased in 47% of the patients by an
average of 16 dB
Improvement persisted at 1-year follow-up
EECP  enhanced external counterpulsation; HF  heart failure; MAP  mean arterial pressure; RAP  refractory angina pectoris; IRLS  International Restless Leg Severity Scale.
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EECP and Future Directions October 16, 2007:1523–31especially aortic insufficiency), or for those with recent
ardiac catheterization, an irregular heart rhythm, severe
ypertension, significant blockages in the leg arteries, or a
istory of deep venous thrombosis (Table 2). For anyone
lse, however, the procedure seems to be quite safe.
uture Directions and Conclusions
hroughout the world, EECP therapy has been studied for
arious potential uses other than heart disease (48–53)
Table 3). Its role in improving endothelial function might
e beneficial in the treatment of patients with Cardiac
yndrome X, which is marked by severe chest pain caused
y myocardial dysfunction, often without detectable athero-
clerosis. Mayo Clinic investigators have reported successful
reatment of Cardiac Syndrome X with severely symptom-
tic coronary endothelial dysfunction in the absence of
bstructive CAD with standard 35-h course of EECP
herapy (54). However, it is important to realize that EECP
herapy is an option for patients with angina refractory to
edical treatment who are not candidates for interventional
r surgical revascularization. The American Heart Associ-
tion recommends it as a Class IIb (Level of Evidence: B)
ntervention for treatment of RAP, among other nonphar-
acological approaches such as neurostimulation (Class IIb,
evel of Evidence: B) and transmyocardial laser revascular-
zation (Class IIa, Level of Evidence: A) (55). The Euro-
ean Society of Cardiology views EECP therapy as an
nteresting modality available for treatment of RAP with
ore clinical trials needed to define its role in treating RAP
56). Enhanced external counterpulsation therapy is a valu-
ble outpatient procedure providing acute and long-term
elief of anginal symptoms and improved quality of life
mong a group of patients with symptomatic ischemic heart
isease with or without congestive HF.
eprint requests and correspondence: Dr. Ozlem Soran, Uni-
ersity of Pittsburgh Cardiovascular Institute, 200 Lothrop Street,
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